non-small cell lung cancer, malignant pleural mesothelioma
Conditions
Interventions
2 mg/day of dexamethasone is administrated for 5 days, two days later from pemetrexed administration
Sponsors
Department of Respiratory medicine and Rheumatology, Tokushima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer or malignant pleural mesothelioma, and adequate pemetrexed treatment 2)ECOG-PS 0-2 3)Patients aged 18 or over 4)Folic acid and vitamin B12 was provided at least 1 week before day 1 5)Hospitalized at starting chemotherapy including pemetrexed 6)Meets the following criteria within 14 days before enrollment (a)Hemoglobin level of more than 9.0 g/dL (b)Neutrophil cout of more than 1500/mm3 (c)Platelet cout of more than 100000/mm3 (d)Total bilirubin: less than 1.5 times the upper limit of normal of the institutional reference range. (e)Aspartate transaminase (AST), alanine transaminase(ALT): less than 3 times the upper limit of normal of the institutional reference range. (f)Creatinine clearance of less than 45mL/min. 7)Written informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients with contraindication of dexamethasone or pemetrexed 2)Using systemic corticosteroid 3)Patients with active infection 4)Using anti-allergenic drug 5)Patients with severe diabetes mellitus that corticosteroids administration is unacceptable 6)Patients with active for hepatitis B antigen and anti-hepatitis C antibody 7)Pregnant / lactating woman, a woman with an intention of pregnancy, a man with a partner who has an intention of pregnancy 8)Combination with cisplatin 9)Patients are judged unqualified for this study by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of rash within 21 days of pemetrexed administration | — |
Countries
Japan
Contacts
Public ContactSakurada Takumi
Tokushima University Hospital Department of Pharmacy
Outcome results
None listed